search
Back to results

ACDF Comparison Trial

Primary Purpose

Cervical Spine Disc Disease, Surgery, Fusion of Spine

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Allograft Fusion
Cohere PEEK Fusion Group
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Spine Disc Disease focused on measuring Anterior Cervical Spine Fusion

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18 or more years of age
  2. Able to provide informed consent
  3. Has documented diagnosis of cervical spine radiculopathy and/or myelopathy
  4. Is undergoing standard-of-care ACDF

Exclusion Criteria:

  1. Prior cervical spine surgery
  2. Single-level ACDF
  3. Has a systemic infection or cervical spine infection
  4. Has a medical condition that may interfere with bone and soft tissue healing
  5. Any condition that, in the opinion of the investigator, may preclude accurate data collection or evaluation.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Allograft Fusion Group

    Cohere PEEK Fusion Group

    Arm Description

    The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.

    The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.

    Outcomes

    Primary Outcome Measures

    Rate of successful fusion.
    To compare post-operative bone fusion following standard-of-care ACDF using allograft fusion or Cohere porous PEEK fusion.

    Secondary Outcome Measures

    Overall success rate - composite score.
    To be considered an overall success, patients have to achieve all of the following: a ≥15 point improvement in their NDI scores, maintenance or improvement in their neurologic status, no serious adverse events related to the implant or surgical procedure, and no subsequent surgery or intervention that is classified as "failure."

    Full Information

    First Posted
    June 12, 2017
    Last Updated
    May 9, 2019
    Sponsor
    Duke University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03187171
    Brief Title
    ACDF Comparison Trial
    Official Title
    Comparison of Outcomes After ACDF Using Allograft Fusion Versus PEEK Fusion: a Prospective Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Funding
    Study Start Date
    December 1, 2018 (Anticipated)
    Primary Completion Date
    April 23, 2019 (Actual)
    Study Completion Date
    April 23, 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Duke University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This research protocol seeks to compare radiological and clinical outcomes of cervical spine disease patients following standard-of-care anterior cervical discectomy and fusion (ACDF) using allograft fusion versus Cohere porous polyetheretherketone (PEEK) fusion device. This clinical study presents little to no additional risk to study subjects beyond those associated with standard-of-care ACDF surgery. Adults age 18 and over who are undergoing an ACDF procedure will be enrolled in the study. The study consists of a completing a series of questionnaires and obtaining radiographs. The primary endpoint of the study will be the rate of successful spinal fusion for each group. For evaluation of the primary endpoint and additional assessments, descriptive statistics including mean, standard deviation, minimum, median, and maximum for continuous variables and frequency distribution for categorical variables will be provided, as well as tabular listings. All complications will be itemized including incidence, duration, and relationship to the device used and/or procedures performed.
    Detailed Description
    This is a prospective randomized comparative outcomes study, in which all subjects who fit the inclusion and exclusion criteria and who agreed to be part of the study will be randomized to either Allograft or Cohere polyetheretherketone (PEEK) fusion group and will be followed for approximately 12 months following surgery according to the standard-of-care. Pain and function will be assessed using neck disability index (NDI), 36-Item Short Form Survey (SF-36), and Numeric Rating Scale (NRS). A trained study team member will record a standardized neurologic examination, including motor, sensory, and reflexes. Neurologic success is defined as maintenance or improvement of all 3 neurologic parameters (motor, sensory, and reflexes). The clinical results will also be assessed using the Japanese Orthopedic Association (JOA) scoring system for cervical myelopathy. Flexion and extension radiographs will be obtained pre-operatively, at 6-months and 12-months after surgery. A CT scan will be obtained at 6 months, if fusion has occurred no CT is needed at 12 months, if fusion did not occur another computerized tomography (CT) scan will obtained at 12 months. From previous literature, successful fusion is defined as ≤2° of angular motion on lateral flexion and extension radiographs, the presence of bridging trabecular bone between the vertebrae being fused, and the absence of any radiolucent zones spanning more than 50% of the allograft surface. Two independent blinded radiologists will assess the radiographs. In the event of disagreement about fusion healing, a third independent reading will be obtained from a third radiologist.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cervical Spine Disc Disease, Surgery, Fusion of Spine, Degenerative Disc Disease
    Keywords
    Anterior Cervical Spine Fusion

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This is a prospective randomized comparative outcomes study, in which all subjects who fit the inclusion and exclusion criteria and who agreed to be part of the study will be randomized to either Allograft or Cohere PEEK fusion group and will be followed for approximately 12 months following surgery according to the standard-of-care.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Allograft Fusion Group
    Arm Type
    Active Comparator
    Arm Description
    The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
    Arm Title
    Cohere PEEK Fusion Group
    Arm Type
    Active Comparator
    Arm Description
    The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
    Intervention Type
    Other
    Intervention Name(s)
    Allograft Fusion
    Intervention Description
    ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
    Intervention Type
    Device
    Intervention Name(s)
    Cohere PEEK Fusion Group
    Other Intervention Name(s)
    Fusion Device, PEEK Cage
    Intervention Description
    Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
    Primary Outcome Measure Information:
    Title
    Rate of successful fusion.
    Description
    To compare post-operative bone fusion following standard-of-care ACDF using allograft fusion or Cohere porous PEEK fusion.
    Time Frame
    18 months
    Secondary Outcome Measure Information:
    Title
    Overall success rate - composite score.
    Description
    To be considered an overall success, patients have to achieve all of the following: a ≥15 point improvement in their NDI scores, maintenance or improvement in their neurologic status, no serious adverse events related to the implant or surgical procedure, and no subsequent surgery or intervention that is classified as "failure."
    Time Frame
    18 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    99 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 18 or more years of age Able to provide informed consent Has documented diagnosis of cervical spine radiculopathy and/or myelopathy Is undergoing standard-of-care ACDF Exclusion Criteria: Prior cervical spine surgery Single-level ACDF Has a systemic infection or cervical spine infection Has a medical condition that may interfere with bone and soft tissue healing Any condition that, in the opinion of the investigator, may preclude accurate data collection or evaluation.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michael Haglund, MD
    Organizational Affiliation
    Duke University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    ACDF Comparison Trial

    We'll reach out to this number within 24 hrs